About Arylsulfatase D
Arylsulfatase D (ARSD) is a protein
from Homo sapiens identified by UniProt accession
P51689, 593 residues long.
MolForge cross-references it against 0 known binders and
33 disease associations.
Target properties
| Protein name | Arylsulfatase D |
| UniProt accession | P51689 |
| Gene | ARSD |
| Organism | Homo sapiens |
| Length | 593 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (33)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.24
- breast cancer · score 0.08
- triple-negative breast cancer · score 0.03
- cancer · score 0.02
- neoplasm · score 0.02
- Pneumonia · score 0.01
- invasive breast ductal carcinoma · score 0.01
- chronic lymphocytic leukemia · score 0.01
- hepatocellular carcinoma · score 0.01
- amyloidosis · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P51689-F1 | alphafold | PREDICTED | 92.42 | — |
Amino-acid sequence (593 residues)
MRSAARRGRA APAARDSLPV LLFLCLLLKT CEPKTANAFK PNILLIMADD LGTGDLGCYG NNTLRTPNID QLAEEGVRLT QHLAAAPLCT PSRAAFLTGR HSFRSGMDAS NGYRALQWNA GSGGLPENET TFARILQQHG YATGLIGKWH QGVNCASRGD HCHHPLNHGF DYFYGMPFTL TNDCDPGRPP EVDAALRAQL WGYTQFLALG ILTLAAGQTC GFFSVSARAV TGMAGVGCLF FISWYSSFGF VRRWNCILMR NHDVTEQPMV LEKTASLMLK EAVSYIERHK HGPFLLFLSL LHVHIPLVTT SAFLGKSQHG LYGDNVEEMD WLIGKVLNAI EDNGLKNSTF TYFTSDHGGH LEARDGHSQL GGWNGIYKGG KGMGGWEGGI RVPGIFHWPG VLPAGRVIGE PTSLMDVFPT VVQLVGGEVP QDRVIDGHSL VPLLQGAEAR SAHEFLFHYC GQHLHAARWH QKDSGSVWKV HYTTPQFHPE GAGACYGRGV CPCSGEGVTH HRPPLLFDLS RDPSEARPLT PDSEPLYHAV IARVGAAVSE HRQTLSPVPQ QFSMSNILWK PWLQPCCGHF PFCSCHEDGD GTP
Explore Arylsulfatase D with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets